Transscleral delivery of bevacizumab-loaded chitosan nanoparticles

Basit Öğe Kaydı
dc.authorid0000-0001-6877-8773
dc.contributor.authorUğurlu, Nagihan
dc.contributor.authorAşık, Mehmet Doğan
dc.contributor.authorÇakmak, Hasan Basri
dc.contributor.authorTuncer, Sema
dc.contributor.authorTürk, Mustafa
dc.contributor.authorÇağıl, Nurullah
dc.contributor.authorDenkbaş, Emir Baki
dc.date.accessioned2019-05-13T09:04:33Z
dc.date.available2019-05-13T09:04:33Z
dc.date.issued2019
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractPurpose: The aim of this study was to synthesize bevacizumabloaded nanoparticles and evaluate their effects on the treatment of posterior segment diseases via subtenon injections. Methods: Bevacizumabloaded chitosan nanoparticles (BLCNs) were synthesized by the ionic gelation method, and their physicochemical characteristics and in vitro release profile were studied. The BLCNs were characterized using atomic force microscopy (AFM), FTIR spectroscopy, dynamic light scattering, and scanning electron microscopy. The BLCNs were delivered into rabbits eyes via posterior subtenon injections. An immunohistochemical evaluation of the ocular tissues was performed, and the vitreous humor and serum bevacizumab levels were measured by ELISA. Results: Bevacizumabloaded chitosan nanoparticles with a diameter of 80 to 380 nm were prepared and characterized. In vitro studies showed that after the first 5 days of the experiment, a significant increase in the drug release maintained the desired drug dosage for 3 weeks. Immunohistochemical in vivo studies revealed that there were BLCNs penetrating through the sclera. Furthermore, the intravitreal bevacizumab concentration reached a maximum concentration of 18 gml, and it decreased to 6 gml after only a week. Conclusion: The results revealed that subtenon injection of BLCNs is a promising alternative to intravitreal injections. In addition to the ELISA studies, immunohistochemical experiments confirmed that BLCNs enable transscleral bevacizumab penetration, and BLCN usage may provide the required bevacizumab levels for the treatment of posterior segment diseases. © 2019 American Scientific Publishers
dc.identifier.citationUğurlu, N., Aşık, M. D., Çakmak, H. B., Tuncer, S., Türk, M., Çağıl, N., Denkbas, E. B. (2019). Transscleral delivery of bevacizumab-loaded chitosan nanoparticles. Journal of Biomedical Nanotechnology, 15(4), 830-838.
dc.identifier.doi10.1166/jbn.2019.2716
dc.identifier.endpage838en_US
dc.identifier.issn1550-7033
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage830en_US
dc.identifier.urihttps://doi.org/10.1166/jbn.2019.2716
dc.identifier.urihttps://hdl.handle.net/11491/1606
dc.identifier.volume15en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmerican Scientific Publishers
dc.relation.ispartofJournal of Biomedical Nanotechnology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBevacizumaben_US
dc.subjectChitosanen_US
dc.subjectNanoparticle Drug Deliveryen_US
dc.subjectSub-Tenon Injectionsen_US
dc.subjectTransscleral Drug Deliveryen_US
dc.titleTransscleral delivery of bevacizumab-loaded chitosan nanoparticles
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu